Her2-Positive Metastatic Colorectal Cancer: Unraveling Game-Changing Treatment Approaches

HER2-Positive Metastatic Colorectal Cancer: Unraveling Game-Changing Treatment Approaches

Overview of recent changes to the treatment landscape for HER2-positive CRC

Targeted therapies for patients with HER2+ colorectal cancer

Tucatinib and trastuzumab in the treatment paradigm of HER2-positive mCRC

MOUNTAINEER: tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal c...

Fulfilling the potential of HER2-targeting in colorectal cancer: update on detection and management

Touch Medical Media

HER 2 amplified metastatic Colorectal cancer

OncBrothers: Practice-Changing Cancer Discussions

Targeting HER2 in colorectal cancer

Targeting HER2 in Colorectal Cancer

Targeted Oncology

32 month follow-up of MOUNTAINEER: tucatinib and trastuzumab in HER2+ mCRC

Molecular Testing and The Role of HER2 in Managing Advanced Colorectal Cancer

MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer

How can HER2-targeted therapies be incorporated into the management of patients with CRC?

Touch Medical Media

Dr. Lieu on HER2-Directed Therapy in CRC

Debate: Are novel targets such as HER2 ready for prime time in colorectal cancer? - No

Dr. Marshall on HER2 Amplification in Colorectal Cancer

Colorectal Cancer: Sequencing and Therapeutic Approaches in First- and Next-Line Treatment

HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

PeerView Oncology

MOUNTAINEER results: trastuzumab and tucatinib for HER2+ mCRC

ASCO 2023 Expert Report on novelties in the treatment of colorectal cancer by S. Stintzing

European Society for Medical Oncology (ESMO)